Predictive and Prognostic Markers in Cancer

Daniel Hayes, MD Clinical Director, Breast Oncology Program Stuart B. Padnos Professor in Breast Cancer Research University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan H&O Can […]

New Strategies to Prevent and Manage Bone Complications in Cancer

Allan Lipton, MD Professor of Medicine/Oncology Penn State University Milton S. Hershey College of Medicine Hershey, Pennsylvania H&O What factors are involved in the risk of bone […]

Importance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Selection

Mara Aspinall, MBA,1 and Gary Palmer, MD, JD, MBA, MPH2 1Chief Executive Officer 2Chief Medical Officer On-Q-ity Waltham, Massachusetts H&O What are circulating tumor cells? MA/GP Circulating tumor cells […]

Abiraterone in Prostate Cancer

Charles Ryan, MD Associate Clinical Professor Department of Medicine UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California H&O What is abiraterone? What is its mechanism […]

HPV and Its Effect on Head and Neck Cancer Prognosis

Maura Gillison, MD, PhD Jeg Coughlin Chair of Cancer Research Professor of Internal Medicine & Epidemiology Ohio State University Medical Center Columbus, Ohio H&O Can you provide […]

Cost-Effectiveness Analysis in Oncology

David Meltzer, MD Associate Professor, Department of Medicine Associated Faculty Member, Harris School and the Department of Economics University of Chicago Chicago, Illinois H&O How has cost-effectiveness analysis […]

Update on CYP2D6 and Its Impact on Tamoxifen Therapy

Matthew P. Goetz, MD Associate Professor of Oncology and Pharmacology Mayo Clinic Rochester, Minnesota H&O What is CYP2D6? What is its significance in regard to tamoxifen and […]

Companion Diagnostics

Robert Becker, Jr, MD, PhD1, and Elizabeth Mansfield, PhD2 1Chief Medical Officer 2Director of the Personalized Medicine Staff OIVD/CDRH/FDA Silver Spring, Maryland H&O What is a companion diagnostic? […]

The National Cancer Institute Experimental Therapeutics Program

James H. Doroshow, MD Director Division of Cancer Treatment and Diagnosis National Cancer Institute Bethesda, Maryland H&O What is the NExT Program? JD The NExT (NCI Experimental Therapeutics) […]

Cost of New Oncology Drugs

Lee Newcomer, MD Senior Vice President, Oncology United Healthcare Edina, Minnesota H&O Why is the cost debate most prominent in oncology as opposed to other diseases? LN There […]

New Treatments for Sarcoma

New Treatments for Sarcoma Ian Judson, MA, MB, BChir, MD, FRCP Professor of Cancer Pharmacology , The Royal Marsden Hospital/Institute of Cancer Research Sycamore House, Sutton, Surrey UK H&O […]

Chronic Myelogenous Leukemia Therapy Beyond Imatinib

Chronic Myelogenous Leukemia Therapy Beyond Imatinib Michael Deininger, MD, PhD, Section Head, Center for Hematologic Malignancies, Non-Transplant, Associate Professor, Oregon Health & Science University, Portland, Oregon H&O What are the […]

Controversies in the Design of Phase II Clinical Trials

Controversies in the Design of Phase II Clinical Trials Lesley Seymour, MD, PhD, Co-Director of the Investigational New Drug Program Director of the Audit and Monitoring Group of […]

BRAF Validation in Melanoma

BRAF Validation in Melanoma Keith Flaherty, MD, Director, Developmental Therapeutics Massachusetts General Hospital Boston, Massachusetts H&O What is BRAF and what role does it play in melanoma? KF V-raf murine […]

Targeting the Anti-apoptotic Signaling Pathway

Targeting the Anti-apoptotic Signaling Pathway Craig Thompson, MD, Scientific Director of the Abramson Institute, Chair of the Department of Cancer Biology, Professor of Medicine, Abramson Family Cancer Research Institute, Philadelphia, PA […]

B-RAF Validation in Melanoma

Neal Rosen, MD, PhD Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York H&O What is B-RAF and what role does it play in melanoma? […]

ALK Inhibitors in Lung Cancer

Elisabeth Heath, MD Associate Professor of Medicine and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan H&O What is the background on the anaplastic lymphoma kinase (ALK) fusion […]